Questions about Lysine Monolaurin
What is monolaurin?
The monoester of glycerol and lauric acid — glyceryl monolaurate (GML), C₁₅H₃₀O₄, CAS 27215-38-9, PubChem CID 14871. Found in coconut oil and human milk; used industrially as surfactant, emulsifier and preservative, with FDA GRAS status for food use.
Is Lysine Monolaurin a single chemical compound?
No. No defined lysine-monolaurin compound appears in the mainstream chemical literature — we checked. The name covers Panacea's formulation research programme pairing monolaurin with L-lysine, presented openly as a combination concept.
What does the monolaurin antimicrobial record actually show?
In-vitro work: Kabara (1972) mapped fatty acids/monoglycerides as antimicrobial agents; Thormar (1987; 1994) reported enveloped-virus inactivation; Schlievert (1992) showed GML blocks toxin production below growth-inhibitory levels, and (2019) that GML contributes to human milk's antimicrobial activity. In vitro means in glassware — not a clinical outcome. See The Research.
Does lysine treat cold sores?
Not according to the strongest reviews. Lysine antagonized arginine-driven HSV growth in tissue culture (Griffith et al., 1981), but Cochrane (2015) found no good clinical evidence and EFSA (2011) found no cause-and-effect relationship. We report both the biochemistry and the verdicts.
Why pair lysine with monolaurin?
The two share a broad neighborhood of biology — enveloped membranes and the herpes literature — and both have food-adjacent regulatory tracks. Pairing them raises legitimate formulation questions about compatibility, dispersion and stability. A hypothesis under study, not a marketed answer.
Is monolaurin the same as lauric acid or coconut oil?
No. Coconut oil is rich in lauric acid; monolaurin is its monoglyceride. The body converts a fraction of ingested lauric acid into monolaurin, and the in-vitro literature generally rates the monoglyceride above the free acid.
Who is behind this site?
Panacea Bio Chem Ltd and its director Bogdan Dicoias, biochemist and AAC designer. The programme is in-house research; parameters remain Panacea intellectual property.
What does Panacea claim for Lysine Monolaurin?
A research-stage formulation programme — nothing more. No finished product, no supplement outcome, no clinical claim. In-house results will be published with methods when they are worth publishing.